Kinase Inhibitors: A Promising Approach for Targeted Cancer Therapy.

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Cancer is a leading cause of non-infectious disease fatalities globally, with increasing incidence projected.
• Current cancer therapies face challenges including drug resistance, limited selectivity, and adverse side effects.
• Kinase inhibitors offer targeted therapy by modulating dysregulated signaling pathways crucial for cancer progression.

Purpose of the Study:

• To systematically review and evaluate recently synthesized kinase inhibitors (2020-2025).
• To focus on inhibitors targeting receptor tyrosine kinases (RTKs) and sucrose non-fermenting-1/AMP-activated protein kinase (Snf1/AMPK) pathways.
• To summarize structural activity relationships and identify future research avenues for anticancer kinase inhibitor development.

Main Methods:

• Literature review of scientific publications and databases.
• Systematic evaluation of kinase inhibitors targeting specific pathways like EGFR, VEGFR, MELK, and acetyl-CoA related pathways.
• Analysis of structural activity relationships for recently developed molecules.

Main Results:

• Identification of promising kinase inhibitors with potential for targeted cancer therapy.
• Summary of novel molecules developed between 2020-2025 targeting key cancer-related pathways.
• Elucidation of structure-activity relationships guiding future drug design.

Conclusions:

• Recent advancements in kinase inhibitor development show promise for overcoming limitations of current cancer therapies.
• Targeting RTKs and Snf1/AMPK pathways represents a key strategy in developing novel anticancer agents.
• Further research into structural activity relationships is crucial for optimizing kinase inhibitors for clinical application.